---
layout: post
title: "沪指六连阳：两市成交额再上万亿 中药板块领涨"
date: 2022-06-07 15:00:21 +0800
categories: emnews
tags: 东财滚动新闻
---
> A股三大指数今日震荡整理，沪指上涨0.17%，日K线收出六连阳。成交额再度突破一万亿，中药、航运港口、石油板块涨幅居前，汽车、风电、半导体板块跌幅居前。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.000001&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 000001_0" data-code="K 000001|1|1" data-code2="K 000001|1|1|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" data-code="BK1040|90|1" data-code2="BK1040|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1040&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1040_0" data-code="K BK1040|90|1" data-code2="K BK1040|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>A股三大指数今日震荡整理，<span id="Info.3257"><a href="http://quote.eastmoney.com/unify/r/1.000001" class="infokey">沪指</a></span>收盘上涨0.17%，日K线收出六连阳，<span id="Info.3260"><a href="http://quote.eastmoney.com/unify/r/0.399001" class="infokey">深证成指</a></span>下跌0.02%，<span id="Info.3259"><a href="http://quote.eastmoney.com/unify/r/0.399006" class="infokey">创业板指</a></span>平盘报收。市场成交额再度突破一万亿元，行业板块涨少跌多，<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>、<span id="bk_90.BK0450"><a href="http://quote.eastmoney.com/unify/r/90.BK0450" class="keytip" data-code="90,BK0450">航运港口</a></span><span id="bkquote_90.BK0450"></span>、石油板块涨幅居前，汽车、风电、<span id="bk_90.BK1036"><a href="http://quote.eastmoney.com/unify/r/90.BK1036" class="keytip" data-code="90,BK1036">半导体</a></span><span id="bkquote_90.BK1036"></span>板块跌幅居前。<br /></p><h3 class="emh3"><span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span><span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span></h3><p><a href="https://stock.eastmoney.com/a/202206072403957452.html">八大券商主题策略：布局疫后复苏下医药消费的机会！中药、CRO等细分领域剖析</a></p><p>每日主题策略讨论，<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span>网汇总八大券商观点，揭秘行业现状，观察行情走势，提前为您把脉A股。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25751162698352802998_w593h461.jpg" width="580" emheight="451" orginial_src="https://dfscdn.dfcfw.com/download/D25751162698352802998_w593h461_o.jpg" style="border:1px solid #d1d1d1;padding:3px;margin:5px 0px;" height="451" /></center><p><strong>湘财<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>：“政策+医药消费刚性+<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>改善+估值优势”构建<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>行业的投资机会</strong></p><p>“政策+医药消费刚性+业绩改善+估值优势”共同构建出<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>行业的投资机会，成本推动构成了短期驱动因素，建议继续关注政策鼓励领域和政策避风港领域。(1)关注现代化中药创新，关注研发实力强、布局大品类(市场大：心脑血管+增速快：儿科用药)的现代化中药创新标的；(2)关注品牌中药，配方、原材料优势共同构筑品牌中药护城河；(3)受益消费升级，关注产业链延伸、品牌优势强的标的。</p><p><strong><span id="stock_0.000686"><a href="http://quote.eastmoney.com/unify/r/0.000686" class="keytip" data-code="0,000686">东北证券</a></span><span id="quote_0.000686"></span>：未来渗透率有望提升 关注中药配方颗粒投资机会</strong></p><p>近年来中药配方颗粒呈现快速增长趋势，在一系列政策引领作用以及中药消费升级趋势下，中药配方颗粒渗透率有望持续提高。根据艾媒咨询数据，近五年中药配方颗粒市场保持快速上涨趋势，2021 年市场规模达346 亿元，同比增长35.5%。渗透率方面，2020 年中药配方颗粒在中药饮片中的占比达到14.31%，创下近年来新高，与发展中药配方颗粒较早的中国台湾地区和日本相比，该渗透率仍然处于较低水平，由于中药配方颗粒相比普通饮片标准化程度高，未来渗透率有望持续攀升。相关标的：<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>、<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>。</p><p><strong><span id="Info.116.01456"><a href="http://quote.eastmoney.com/unify/r/116.01456" class="keytip" data-code="116,01456">国联证券</a></span>：新冠仍为市场热点 关注核酸检测、疫苗等领域</strong></p><p>展望6月，疫情影响逐步消退，建议关注受益于疫情或受疫情影响较小的领域如核酸检测、医疗新基建、口服肿瘤靶向药、CXO 等，以及刚需恢复的领域如疫苗、生命科学上游等：1)医疗新基建：重点推荐<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>、<span id="stock_0.301235"><a href="http://quote.eastmoney.com/unify/r/0.301235" class="keytip" data-code="0,301235">华康医疗</a></span><span id="quote_0.301235"></span>等；2)疫苗：重点推荐<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>、<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>；3)核酸检测：建议关注<span id="stock_1.688289"><a href="http://quote.eastmoney.com/unify/r/1.688289" class="keytip" data-code="1,688289">圣湘生物</a></span><span id="quote_1.688289"></span>、<span id="stock_1.603882"><a href="http://quote.eastmoney.com/unify/r/1.603882" class="keytip" data-code="1,603882">金域医学</a></span><span id="quote_1.603882"></span>、<span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span>、<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>等；4)口服肿瘤靶向药：重点推荐<span id="stock_0.300558"><a href="http://quote.eastmoney.com/unify/r/0.300558" class="keytip" data-code="0,300558">贝达药业</a></span><span id="quote_0.300558"></span>，建议关注艾力斯等；5)生命科学上游：重点推荐诺唯赞，建议关注<span id="stock_0.301080"><a href="http://quote.eastmoney.com/unify/r/0.301080" class="keytip" data-code="0,301080">百普赛斯</a></span><span id="quote_0.301080"></span>、<span id="stock_0.301047"><a href="http://quote.eastmoney.com/unify/r/0.301047" class="keytip" data-code="0,301047">义翘神州</a></span><span id="quote_0.301047"></span>等；6)CXO:重点关注<span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>、<span id="stock_1.688131"><a href="http://quote.eastmoney.com/unify/r/1.688131" class="keytip" data-code="1,688131">皓元医药</a></span><span id="quote_1.688131"></span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>，建议关注<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>等。</p><p><strong><span id="stock_1.600109"><a href="http://quote.eastmoney.com/unify/r/1.600109" class="keytip" data-code="1,600109">国金证券</a></span><span id="quote_1.600109"></span>：关注临床前<span id="bk_90.BK0899"><a href="http://quote.eastmoney.com/unify/r/90.BK0899" class="keytip" data-code="90,BK0899">CRO</a></span><span id="bkquote_90.BK0899"></span>和疫情防控及复工复产条线的投资机遇</strong></p><p>创新药研发进展不断，关注新品种放量和头部药企的商业化能力价值，以及新冠研发进展。①创新药研发进展不断：驯鹿生物/<span id="Info.116.01801"><a href="http://quote.eastmoney.com/unify/r/116.01801" class="keytip" data-code="116,01801">信达生物</a></span>的CAR-T 细胞疗法伊基仑赛注射液的上市申请获得NMPA 受理；杭州多禧生物的ADC 平台与杨森制药达成合作并获得股权投资，多项创新药获得临床试验批准；</p><p>②看好新冠相关研发方向：国内小分子药物针对新冠轻中症的临床试验以及新冠疫苗研发陆续取得进展，建议关注国内针对新冠轻中症和中重症的进展较快的小分子药物研发企业。</p><p>投资建议：看好医药创新成长，关注临床前<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0899" class="em_stock_key_common" data-code="90,BK0899">CRO</span> 和疫情防控及复工复产条线的投资机遇。建议关注：<span id="Info.116.06127"><a href="http://quote.eastmoney.com/unify/r/116.06127" class="keytip" data-code="116,06127">昭衍新药</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>、<span id="stock_1.600267"><a href="http://quote.eastmoney.com/unify/r/1.600267" class="keytip" data-code="1,600267">海正药业</a></span><span id="quote_1.600267"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603456" class="em_stock_key_common" data-code="1,603456">九洲药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688131" class="em_stock_key_common" data-code="1,688131">皓元医药</span>等。</p><p><strong><span id="stock_1.600918"><a href="http://quote.eastmoney.com/unify/r/1.600918" class="keytip" data-code="1,600918">中泰证券</a></span><span id="quote_1.600918"></span>：布局疫后复苏下医药消费的机会！建议积极布局三个方向</strong></p><p>进入6月，上海等地逐步复工复产，同时Q2业绩逐渐明朗，建议积极布局复苏下医药消费的机会，同时把握Q2 业绩强劲的板块和个股，如基本面强劲、业绩具有确定性的医药制造板块等。</p><p>目前上海、北京等疫情逐步得到控制，前期因疫情封控导致的物流缺乏、<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>暂停等开始逐渐恢复，在复苏的大趋势下，建议积极布局以下3 个方向：1)封控解除流量恢复，叠加暑期旺盛需求，如<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0727" class="em_stock_key_common" data-code="90,BK0727">医疗服务</span>、连锁药店、眼科产业链、消费属性药械等，建议重点关注<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0727" class="em_stock_key_common" data-code="90,BK0727">医疗服务</span>龙头<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>、<span id="Info.116.06078"><a href="http://quote.eastmoney.com/unify/r/116.06078" class="keytip" data-code="116,06078">海吉亚医疗</a></span>、<span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>，连锁药店<span id="stock_1.603939"><a href="http://quote.eastmoney.com/unify/r/1.603939" class="keytip" data-code="1,603939">益丰药房</a></span><span id="quote_1.603939"></span>、<span id="stock_1.603883"><a href="http://quote.eastmoney.com/unify/r/1.603883" class="keytip" data-code="1,603883">老百姓</a></span><span id="quote_1.603883"></span>、<span id="stock_1.603233"><a href="http://quote.eastmoney.com/unify/r/1.603233" class="keytip" data-code="1,603233">大参林</a></span><span id="quote_1.603233"></span>、<span id="stock_0.002727"><a href="http://quote.eastmoney.com/unify/r/0.002727" class="keytip" data-code="0,002727">一心堂</a></span><span id="quote_0.002727"></span>等，眼科诊疗<span id="stock_0.300595"><a href="http://quote.eastmoney.com/unify/r/0.300595" class="keytip" data-code="0,300595">欧普康视</a></span><span id="quote_0.300595"></span>、<span id="stock_0.300573"><a href="http://quote.eastmoney.com/unify/r/0.300573" class="keytip" data-code="0,300573">兴齐眼药</a></span><span id="quote_0.300573"></span>、<span id="stock_1.688050"><a href="http://quote.eastmoney.com/unify/r/1.688050" class="keytip" data-code="1,688050">爱博医疗</a></span><span id="quote_1.688050"></span>等，消费属性药械企业<span id="stock_0.000661"><a href="http://quote.eastmoney.com/unify/r/0.000661" class="keytip" data-code="0,000661">长春高新</a></span><span id="quote_0.000661"></span>、<span id="stock_0.300357"><a href="http://quote.eastmoney.com/unify/r/0.300357" class="keytip" data-code="0,300357">我武生物</a></span><span id="quote_0.300357"></span>等；2)物流恢复，压制供给因素解除，如疫苗、血制品等，建议重点关注二类疫苗企业<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603392" class="em_stock_key_common" data-code="1,603392">万泰生物</span>、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>、<span id="stock_0.300841"><a href="http://quote.eastmoney.com/unify/r/0.300841" class="keytip" data-code="0,300841">康华生物</a></span><span id="quote_0.300841"></span>、<span id="stock_1.688276"><a href="http://quote.eastmoney.com/unify/r/1.688276" class="keytip" data-code="1,688276">百克生物</a></span><span id="quote_1.688276"></span>等，血制品龙头企业<span id="stock_1.600161"><a href="http://quote.eastmoney.com/unify/r/1.600161" class="keytip" data-code="1,600161">天坛生物</a></span><span id="quote_1.600161"></span>、<span id="stock_0.002007"><a href="http://quote.eastmoney.com/unify/r/0.002007" class="keytip" data-code="0,002007">华兰生物</a></span><span id="quote_0.002007"></span>、<span id="stock_0.300294"><a href="http://quote.eastmoney.com/unify/r/0.300294" class="keytip" data-code="0,300294">博雅生物</a></span><span id="quote_0.300294"></span>、<span id="stock_0.000403"><a href="http://quote.eastmoney.com/unify/r/0.000403" class="keytip" data-code="0,000403">派林生物</a></span><span id="quote_0.000403"></span>等；3)上海地区复工复产受益标的：<span id="stock_1.603520"><a href="http://quote.eastmoney.com/unify/r/1.603520" class="keytip" data-code="1,603520">司太立</a></span><span id="quote_1.603520"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>、<span id="stock_1.688133"><a href="http://quote.eastmoney.com/unify/r/1.688133" class="keytip" data-code="1,688133">泰坦科技</a></span><span id="quote_1.688133"></span>等。</p><p>同时新冠疫情常态化防控下，新冠口服药、新型疫苗、核酸检测等产业链有望全年催化，建议关注新冠口服药进展靠前的标的如<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、<span id="stock_1.603229"><a href="http://quote.eastmoney.com/unify/r/1.603229" class="keytip" data-code="1,603229">奥翔药业</a></span><span id="quote_1.603229"></span>等；加强针接种及新型疫苗布局的企业如<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span id="stock_0.300142"><a href="http://quote.eastmoney.com/unify/r/0.300142" class="keytip" data-code="0,300142">沃森生物</a></span><span id="quote_0.300142"></span>、<span id="Info.116.02196"><a href="http://quote.eastmoney.com/unify/r/116.02196" class="keytip" data-code="116,02196">复星医药</a></span>等；常态核酸检测贡献稳定现金流的受益标的如<span web="1" href="http://quote.eastmoney.com/unify/r/1.603882" class="em_stock_key_common" data-code="1,603882">金域医学</span>、<span id="stock_0.300244"><a href="http://quote.eastmoney.com/unify/r/0.300244" class="keytip" data-code="0,300244">迪安诊断</a></span><span id="quote_0.300244"></span>等。</p><p><strong><span id="Info.116.06178"><a href="http://quote.eastmoney.com/unify/r/116.06178" class="keytip" data-code="116,06178">光大证券</a></span>：紧抓补短板、高景气与疫后修复三大医疗主线</strong></p><p>紧抓补短板、高景气与疫后修复三大主线。基于疫情常态化及防疫措施，寻找补短板、高景气与疫后修复方向：未来应当基于疫情对社会和医疗卫生系统的长期影响寻找投资主线，包括：1)补齐短板，如应对疫情威胁必需的新冠特效药产业链、医疗新基建、疫苗接种等；2)景气度较高，本身受到疫情影响不大，或政策支持下有望迎来景气度提升的方向，如CDMO、中医药等；3)疫后修复，在疫情期间受到社会活动和医院常规客流量下降的负面影响，但后续将迎来修复的医疗消费、零售药店等。</p><p>紧抓补短板、高景气度与疫后修复三大主线：长期来看疫情对人类社会的影响将趋于弱化，但短期依然会对社会经济活动和医药行业产生重大影响，基于疫情的常态化及防疫措施，补齐防疫所需的短板、受疫情影响小或政策支持力度大的高景气度方向、疫情受损后修复的方向有望成为下半年的投资主线。分别推荐<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>(A+H)、<span id="stock_0.300636"><a href="http://quote.eastmoney.com/unify/r/0.300636" class="keytip" data-code="0,300636">同和药业</a></span><span id="quote_0.300636"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、<span id="stock_1.600587"><a href="http://quote.eastmoney.com/unify/r/1.600587" class="keytip" data-code="1,600587">新华医疗</a></span><span id="quote_1.600587"></span>、<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>(A+H)、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01951" class="em_stock_key_common" data-code="116,01951">锦欣生殖</span>(H)、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603939" class="em_stock_key_common" data-code="1,603939">益丰药房</span>、<span id="stock_0.000915"><a href="http://quote.eastmoney.com/unify/r/0.000915" class="keytip" data-code="0,000915">华特达因</a></span><span id="quote_0.000915"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300142" class="em_stock_key_common" data-code="0,300142">沃森生物</span>。</p><p><strong><span id="stock_1.600369"><a href="http://quote.eastmoney.com/unify/r/1.600369" class="keytip" data-code="1,600369">西南证券</a></span><span id="quote_1.600369"></span>：在医保压力常态化和后疫情时代 重点寻找“穿越医保”和“疫情脱敏”品种</strong></p><p>在医保压力常态化和后疫情时代，重点寻找“穿越医保”和“疫情脱敏”品种。未来医保压力将成为常态，一方面，我们认为药械龙头企业比如<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>等有望通过“持续创新+国际化”有望穿越“医保结界”；另一方面，医保免疫仍是较好选择，针对下游ToC端而言，重点关注不占医保的品种比如自费生物药、中药消费品、医美上游产品等；而产业链上游ToB 端相对政策免疫，比如创<span id="stock_0.300832"><a href="http://quote.eastmoney.com/unify/r/0.300832" class="keytip" data-code="0,300832">新产业</a></span><span id="quote_0.300832"></span>链CXO 板块，设备板块包括药机设备、药房自动化设备、耗材生产设备等，生命科学试剂耗材领域等。后疫情时代，我们认为重点关注疫情“脱敏”领域，1)不受新冠干扰的疫苗品种或疫苗超跌品种；2)PEG小于1，长期基本面趋势向上的低估值或低预期的品种；3)此前疫情受损、未来需求复苏的医疗服务品种等。</p><p><strong>东莞<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：目前医药生物行业整体PE已回落至行业近十年来估值的底部</strong></p><p>随着国内散点疫情趋于控制，预计下半年行业增速有望回升。从政策展望来看，下半年第七批药品集采、第三批<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>集采、医保谈判等即将开展，预计对市场的负面冲击有限。从估值上看，目前行业整体PE已回落至行业近十年来估值的底部，相对<span id="Info.3261"><a href="http://quote.eastmoney.com/unify/r/1.000300" class="infokey">沪深300</a></span>整体PE溢价率也已处于行业近十年来溢价率新低位置。但行业内细分板块分化较大，建议关注：在手订单丰富、景气度有望延续的CXO；有望受益于国产替代率上升的科学服务；政策支持方面不改的民营医院；有望受益于医疗新基建和国产替代的医疗设备；有望受益于赛道景气度提升的眼科、医美；集采相对温和、政策相对积极的中药创新药和品牌中药；研发进展推进较快的新冠特效药公司及产业链上相关合作企业等。</p><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>时报网）</p>

<http://finance.eastmoney.com/news/1345,202206072404122260.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)